

**QINLOCK
(ripretinib)**

Pre - PA Allowance

None

Prior-Approval Requirements

Age 18 years of age and older

Diagnosis

Patient must have the following:

1. Advanced gastrointestinal stromal tumor (GIST)
 - a. Patient has received prior treatment with 3 or more kinase inhibitors, including imatinib

AND ALL of the following:

- a. Prescriber agrees to monitor for Palmar-Plantar Erythrodysesthesia Syndrome
- b. Prescriber agrees to perform a dermatologic evaluation prior to initiating Qinlock and routinely during treatment
- c. Ejection fraction has been assessed by echocardiogram or MUGA scan prior to initiating Qinlock
- d. **NO** uncontrolled hypertension
- e. Females of reproductive potential **only**: patient will be advised to use effective contraception during treatment with Qinlock and for 1 week after the final dose
- f. Males with female partners of reproductive potential **only**: patient will be advised to use effective contraception during treatment with Qinlock and for 1 week after the final dose

Prior - Approval Limits

Quantity 540 tablets per 90 days

Duration 12 months

Prior – Approval *Renewal* Requirements



**BlueCross
BlueShield**

Federal Employee Program.

**QINLOCK
(ripretinib)**

Age 18 years of age and older

Diagnosis

Patient must have the following:

1. Advanced gastrointestinal stromal tumor (GIST)

AND ALL of the following:

- a. **NO** disease progression or unacceptable toxicity
- b. Prescriber agrees to monitor for Palmar-Plantar Erythrodysesthesia Syndrome
- c. Prescriber agrees to perform a dermatologic evaluations routinely during treatment
- d. Females of reproductive potential **only**: patient will be advised to use effective contraception during treatment with Qinlock and for 1 week after the final dose
- e. Males with female partners of reproductive potential **only**: patient will be advised to use effective contraception during treatment with Qinlock and for 1 week after the final dose

Prior - Approval *Renewal* Limits

Same as above